Total Visits

Views
HAPTOGLOBIN PHENOTYPE, HDL-CHOLESTEROL RAISING THERAPY (FIBRATE), AND RISK OF CARDIOVASCULAR DISEASE EVENTS WITHIN THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES (ACCORD) LIPID TRIAL85

Total Visits Per Month

November 2023December 2023January 2024February 2024March 2024April 2024May 2024
HAPTOGLOBIN PHENOTYPE, HDL-CHOLESTEROL RAISING THERAPY (FIBRATE), AND RISK OF CARDIOVASCULAR DISEASE EVENTS WITHIN THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES (ACCORD) LIPID TRIAL07110451

File Visits

Views
Warren-Rachel-MSc-CH&E-August-2020.pdf307

Top country views

Views
United States57
Vietnam5
Ireland4
Canada3
Bulgaria2
China2
Sweden2
Australia1
Indonesia1
India1

Top cities views

Views
Blue Bell11
Houston9
Oakland8
Wilmington6
Fairfield5
Hanoi5
Dublin4
Palo Alto3
Halifax2
Menlo Park2